Prothelia
www.prothelia.comProthelia is developing recombinant human Laminin-111 (rhLAM-111) for treatment of congenital muscular dystrophy type 1A. This form of muscular dystrophy is also referred to as MDC1A, Merosin deficiency or LAMA2 deficiency.
Read more
Prothelia is developing recombinant human Laminin-111 (rhLAM-111) for treatment of congenital muscular dystrophy type 1A. This form of muscular dystrophy is also referred to as MDC1A, Merosin deficiency or LAMA2 deficiency.
Read more
Country
State
Massachusetts
City (Headquarters)
Boston
Industry
Employees
1-10
Founded
2008
Estimated Revenue
$1 to $1,000,000
Social
Employees statistics
View all employeesPotential Decision Makers
Chief Scientific Officer
Email ****** @****.comPhone (***) ****-****Director
Email ****** @****.comPhone (***) ****-****Scientific Advisor
Email ****** @****.comPhone (***) ****-****
Reach decision makers at Prothelia
Free credits every month!
Prothelia FAQ
Boston, United States
Biotechnology Research
